Morgan Stanley
SGMO

Morgan Stanley’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Morgan Stanley’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$105K Sell
423,265
-487
-0.1% -$194 ﹤0.01% 6138
2025
Q4 		$178K Sell
423,752
-168,401
-28% -$89.3K ﹤0.01% 5970
2025
Q3 		$399K Buy
592,153
+19,385
+3% +$10.4K ﹤0.01% 5609
2025
Q2 		$310K Sell
572,768
-172,993
-23% -$103K ﹤0.01% 5673
2025
Q1 		$489K Sell
745,761
-1,135,500
-60% -$1.2M ﹤0.01% 5332
2024
Q4 		$1.92M Buy
1,881,261
+1,528,514
+433% +$2.79M ﹤0.01% 4722
2024
Q3 		$306K Sell
352,747
-428,650
-55% -$314K ﹤0.01% 5599
2024
Q2 		$280K Buy
781,397
+247,326
+46% +$134K ﹤0.01% 5531
2024
Q1 		$358K Sell
534,071
-1,283,941
-71% -$931K ﹤0.01% 5466
2023
Q4 		$988K Buy
1,818,012
+1,054,792
+138% +$486K ﹤0.01% 5301
2023
Q3 		$458K Sell
763,220
-13,916
-2% -$14.9K ﹤0.01% 5206
2023
Q2 		$1.01M Sell
777,136
-808,796
-51% -$1.11M ﹤0.01% 4822
2023
Q1 		$2.79M Buy
1,585,932
+524,761
+49% +$1.5M ﹤0.01% 4246
2022
Q4 		$3.33M Sell
1,061,171
-33,078
-3% -$128K ﹤0.01% 4095
2022
Q3 		$5.36M Sell
1,094,249
-320,276
-23% -$1.65M ﹤0.01% 3627
2022
Q2 		$5.86M Buy
1,414,525
+555,560
+65% +$2.4M ﹤0.01% 3621
2022
Q1 		$4.99M Sell
858,965
-430,619
-33% -$2.56M ﹤0.01% 3689
2021
Q4 		$9.67M Buy
1,289,584
+283,829
+28% +$2.47M ﹤0.01% 2978
2021
Q3 		$9.06M Buy
1,005,755
+114,608
+13% +$1.13M ﹤0.01% 3019
2021
Q2 		$10.7M Buy
891,147
+176,775
+25% +$2M ﹤0.01% 2902
2021
Q1 		$8.95M Sell
714,372
-100,883
-12% -$1.36M ﹤0.01% 2769
2020
Q4 		$12.7M Buy
815,255
+479,407
+143% +$5.62M ﹤0.01% 2270
2020
Q3 		$3.17M Sell
335,848
-64,099
-16% -$693K ﹤0.01% 3185
2020
Q2 		$3.58M Buy
399,947
+4,618
+1% +$42.8K ﹤0.01% 3018
2020
Q1 		$2.52M Sell
395,329
-419,362
-51% -$3.11M ﹤0.01% 3150
2019
Q4 		$6.82M Buy
814,691
+16,455
+2% +$151K ﹤0.01% 2845
2019
Q3 		$7.22M Buy
798,236
+374,935
+89% +$4.21M ﹤0.01% 2469
2019
Q2 		$4.56M Sell
423,301
-107,667
-20% -$1.15M ﹤0.01% 3008
2019
Q1 		$5.07M Sell
530,968
-25,457
-5% -$260K ﹤0.01% 2696
2018
Q4 		$6.39M Sell
556,425
-36,368
-6% -$452K ﹤0.01% 2600
2018
Q3 		$10M Sell
592,793
-322,390
-35% -$4.9M ﹤0.01% 2413
2018
Q2 		$13M Sell
915,183
-325,556
-26% -$5.41M ﹤0.01% 2082
2018
Q1 		$23.6M Buy
1,240,739
+818,342
+194% +$17.5M 0.01% 1522
2017
Q4 		$6.93M Sell
422,397
-282,727
-40% -$4.21M ﹤0.01% 2740
2017
Q3 		$10.6M Buy
705,124
+308,148
+78% +$3.41M ﹤0.01% 2213
2017
Q2 		$3.49M Buy
396,976
+88,271
+29% +$566K ﹤0.01% 3261
2017
Q1 		$1.6M Sell
308,705
-105,845
-26% -$425K ﹤0.01% 4012
2016
Q4 		$1.26M Buy
414,550
+81,916
+25% +$298K ﹤0.01% 4292
2016
Q3 		$1.54M Buy
332,634
+19,723
+6% +$100K ﹤0.01% 3720
2016
Q2 		$1.81M Sell
312,911
-15,082
-5% -$96.1K ﹤0.01% 3506
2016
Q1 		$1.98M Sell
327,993
-17,351
-5% -$104K ﹤0.01% 3363
2015
Q4 		$3.15M Sell
345,344
-51,525
-13% -$397K ﹤0.01% 3095
2015
Q3 		$2.24M Sell
396,869
-2,835
-0.7% -$23.4K ﹤0.01% 3407
2015
Q2 		$4.43M Sell
399,704
-32,780
-8% -$423K ﹤0.01% 2895
2015
Q1 		$6.78M Sell
432,484
-11,070
-2% -$171K ﹤0.01% 2457
2014
Q4 		$6.75M Sell
443,554
-41,559
-9% -$505K ﹤0.01% 2432
2014
Q3 		$5.23M Buy
485,113
+33,544
+7% +$438K ﹤0.01% 2600
2014
Q2 		$6.89M Sell
451,569
-33,706
-7% -$485K ﹤0.01% 2371
2014
Q1 		$8.77M Buy
485,275
+70,912
+17% +$1.37M ﹤0.01% 2061
2013
Q4 		$5.76M Buy
414,363
+11,446
+3% +$132K ﹤0.01% 2448
2013
Q3 		$4.22M Sell
402,917
-196,462
-33% -$1.95M ﹤0.01% 2596
2013
Q2 		$4.68M Buy
+599,379
New +$5.23M ﹤0.01% 2391

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Morgan Stanley's SGMO Position: Q1 2026 in Review

Morgan Stanley reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 0.11% in Q1 2026, selling an estimated $194 and leaving 423,265 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #6138.

Morgan Stanley first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $23.6M in Q1 2018. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Morgan Stanley held 423,265 shares of SANGAMO THERAPEUTICS INC worth $105K as of Q1 2026.
  • Morgan Stanley sold 487 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $194.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6138 holding.
  • Morgan Stanley first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
  • Morgan Stanley's SANGAMO THERAPEUTICS INC position peaked at $23.6M in Q1 2018.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.